Comparison
DSIP vs. Bremelanotide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
62568-57-4
189691-06-3
Molecular weight
848.81 g/mol
1025.18 g/mol
Half-life
0.1 h
2.7 h
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluAc-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHMechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
5
of which in humans
1
5
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
2